SCHEMBL12445443

SCHEMBL12445443

CC(=O)NCCOCCOCCC(=O)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MTNR1A P48039 5/20 0.38
MTNR1B P49286 5/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPK1 P28482 2/20 0.38
HIF1A Q16665 1/20 0.38
ALDH1A1 P00352 3/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 2/20 0.35
ADRA1A P35348 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
USP2 O75604 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
PAOX Q6QHF9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27375087 1.00 MEN1 (0.50) MEN1KMT2AMTNR1AMTNR1BKDM4E
SCHEMBL17921779 0.98 MEN1 (0.47) MEN1KMT2AMTNR1AMTNR1BKDM4E
SCHEMBL18866794 0.87 MEN1 (0.41) MEN1KMT2AMTNR1AMTNR1BKDM4E
SCHEMBL22790989 0.86 MEN1 (0.50) MEN1KMT2AMTNR1AMTNR1BKDM4E
SCHEMBL22861923 0.86 MEN1 (0.50) MEN1KMT2AMTNR1AMTNR1BKDM4E
SCHEMBL23945213 0.86 MEN1 (0.50) MEN1KMT2AMTNR1AMTNR1BKDM4E
SCHEMBL25128825 0.86 KMT2A (0.59) MEN1KMT2AMTNR1AKDM4EMAPK1
SCHEMBL25129535 0.86 KMT2A (0.59) MEN1KMT2AMTNR1AKDM4EMAPK1
SCHEMBL23386933 0.86 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDTSHR
SCHEMBL27371560 0.86 KMT2A (0.59) MEN1KMT2AMTNR1AKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293714-B2 Anti-angiogenic compounds COVX TECHNOLOGY IRELAND, LTD. (IE) 2012-10-23 US disclosed
US-8293714-B2 Anti-angiogenic compounds COVX TECHNOLOGY IRELAND, LTD. (IE) 2012-10-23 US disclosed
US-8288349-B2 Anti-angiogenic compounds COVX TECHNOLOGY IRELAND, LTD. (IE) 2012-10-16 US disclosed
EP-2089425-B1 ANTI-ANGIOGENIC COMPOUNDS COVX TECHNOLOGIES IRELAND LTD (IE) 2011-08-17 EP disclosed
US-20100003267-A1 ANTI-ANGIOGENIC COMPOUNDS COVX TECHNOLOGIES IRELAND, LIMITED 2010-01-07 US disclosed
US-20100003267-A1 ANTI-ANGIOGENIC COMPOUNDS COVX TECHNOLOGIES IRELAND, LIMITED 2010-01-07 US disclosed
US-20080166364-A1 Conjugated to antibody; thrombospondin receptor targeting COVX TECHNOLOGY IRELAND, LTD. (IE) 2008-07-10 US disclosed
US-20080166364-A1 Conjugated to antibody; thrombospondin receptor targeting COVX TECHNOLOGY IRELAND, LTD. (IE) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003267-A1 ANTI-ANGIOGENIC COMPOUNDS VEGFA, FLT4, FLT1 MEN1 3298/4885KMT2A 4489/4885MTNR1A 1333/4885
US-20080166364-A1 Conjugated to antibody; thrombospondin receptor targeting TEK, KDR, FLT4 MEN1 2043/4885KMT2A 3959/4885MTNR1A 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.